News

Chr. Hansen: probiotics can help minimise flu cost

2 Sep 2019

Chr. Hansen reports that a new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness.

In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.

Chr. Hansen: probiotics can help minimise flu cost

Flu-like sickness can take its toll on workforce productivity, health care systems and families with young children, the company notes, and is estimated to have an annual burden on the US economy of $11.2 billion .

According to Chr. Hansen, data from numerous studies already shows a positive correlation between taking certain probiotics and reducing the number of incidents, duration and severity of flu-like sickness. This new study builds upon existing data, to assess the potential health economic impact of probiotics in the US primary care setting. The findings show the significant savings potential taking probiotics can have by reducing the number of sick days, visits to the doctor and prescriptions.

Flu-like sickness is a wide-ranging category including a fever of at least 100°F (37.8°C) and a cough or sore throat. On average over the last five years, there have been 33 million symptomatic cases in the US each year.

“Probiotics are already well established in the healthcare industry, and numerous studies have highlighted the therapeutic potential of specific probiotic strains in helping to maintain a healthy immune system and supporting the defense against harmful bacteria. In addition to the health benefits to an individual, this study demonstrates that taking probiotics also contributes to reducing costs to society and reducing the use of antibiotics. We believe that the impact of probiotics on healthcare will continue to grow in the years to come as we continue to unlock the potential of good bacteria,” said Andrew Scorey, senior vice president, Chr. Hansen Human Health.

Chr. Hansen points out that, according to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security and development today, and it is expected to exceed cancer as the main cause of death by 2050. It is estimated that more than one in three of the antibiotics prescribed to treat flu-like sickness in the US are redundant.

The new study reveals that in the US, some 2.2 million antibiotic courses could be avoided each year if the population takes probiotics.

“We already know that the overuse of antibiotics can cause bacteria to become resistant, meaning current treatments will no longer work. This study provides further evidence of how probiotics and ‘good bacteria’ can respond to some of the world’s biggest challenges,” said Scorey.

The results of the study are published in the journal Frontiers in Pharmacology and were authored and reviewed by independent industry and academic experts. Chr. Hansen sponsored the development of a new simulation model used in the study. The publication title is: Probiotics reduce healthcare cost and societal impact of flu-like respiratory tract infections in the USA: An economic modeling study.

The underlying data used in the study came from two independent reviews: York Health Economics Consortium (YHEC) and Cochrane. The clinical trials in these reviews used 22 probiotic strains, including Chr. Hansen’s Lactobacillus rhamnosus and Bifidobacterium animalis.

“This study builds on independent clinical trials and translates the clinical findings into cost and impact on primary health care. The results present a very strong case for probiotics. At Chr. Hansen, we will continue to build on these findings looking closely into how specific strains can support this health area. As a result of this study, we now have a new simulation model that will provide us with new ways to work with data in future studies,” said Adam Baker, senior manager, Human Health Development at Chr. Hansen.

Chr. Hansen owns some of the world’s best documented probiotic strains. The large number of scientific publications and clinical studies on these strains indicate that they may have beneficial effects on the immune functions.

Related news

Dog food brand shakes up sector with ‘human-quality’ meat

Dog food brand shakes up sector with ‘human-quality’ meat

17 Apr 2026

UK pet food startup Years designs its premium meals based on a dog’s breed, life stage, and health, using wholefood recipes and clear plastic packaging.

Read more 
PepsiCo targeting 'big opportunity' in out-of-home snacking

PepsiCo targeting 'big opportunity' in out-of-home snacking

15 Apr 2026

PepsiCo is “restaging” its biggest brands – Lay's, Tostitos, Gatorade, and Quaker – to strengthen their out-of-home positioning as consumers continue to eat outside of the home, its CEO says.

Read more 
Emissions-reduction technologies can help brands hit green goals

Emissions-reduction technologies can help brands hit green goals

14 Apr 2026

Emissions-reduction technologies can help global manufacturers lower their environmental impact while increasing operational efficiency and making savings.

Read more 
Securing sweetness in bakery, without the sweetener effect

Securing sweetness in bakery, without the sweetener effect

13 Apr 2026

EFSA has confirmed sucralose cannot be used in most bakery applications. So, which sweeteners can manufacturers of healthy indulgent baked goods use?

Read more 
Princes Group introduces 5% price increase due to Iran war

Princes Group introduces 5% price increase due to Iran war

10 Apr 2026

UK company Princes Group has set a minimum 5% price increase on its products, making it the one of first major suppliers to openly raise prices due to the Iran war.

Read more 
The rise of CPG disruptor brands

The rise of CPG disruptor brands

9 Apr 2026

Bold, relevant, and agile disruptor brands, such as Olly and Poppi are reshaping consumer packaged goods (CPG) and driving growth in stagnant areas – reframing everything about the categories they are showing up in, say experts.

Read more 
Unreviewed GRAS chemicals in US products risk consumer confidence

Unreviewed GRAS chemicals in US products risk consumer confidence

8 Apr 2026

There are over 100 unreviewed GRAS chemicals in US food and drink products, undermining consumer trust, according to an analysis.

Read more 
Rising automation requires clear risk management strategy

Rising automation requires clear risk management strategy

6 Apr 2026

Automation is helping manufacturers reduce bottlenecks but it also comes with risks. Successful brands will have clear risk management strategies.

Read more 
Partnership between Tesco and Buy Women Built spotlights female-founded brands

Partnership between Tesco and Buy Women Built spotlights female-founded brands

2 Apr 2026

The partnership featured dedicated Buy Women Built in-store displays across more than 150 Tesco UK stores, showcasing female-founded brands.

Read more 
General Mills CEO: We are 'innovating on how we innovate' through AI

General Mills CEO: We are 'innovating on how we innovate' through AI

27 Mar 2026

Artificial intelligence (AI) tools are adding speed, depth and innovative angles to several areas of business at General Mills and will prove invaluable in enhancing brand traction globally, its CEO says.

Read more